v3.25.2
Segment Reporting - Summary of Disaggregated Amounts Research and Development Expenses and Segment Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Primary program research and development expenses [1] $ 16,708   $ 13,579   $ 31,447 $ 26,043
Total other research and development expenses 3,658   3,438   7,172 6,478
Research and development operating costs and expenses excluding non-cash stock-based compensation 20,366   17,017   38,619 32,521
General and administrative expense excluding non-cash stock-based compensation 8,371   3,944   15,551 8,626
Other segment income (expense), net [2] 1,664   1,282   2,870 1,442
Net loss (30,401) $ (26,639) (22,243) $ (20,346) (57,040) (42,589)
Payroll and Benefits [Member]            
Segment Reporting Information [Line Items]            
Total other research and development expenses 3,210   2,946   6,098 5,603
Occupancy and Other Overhead and Operating Costs [Member]            
Segment Reporting Information [Line Items]            
Total other research and development expenses $ 448   $ 492   $ 1,074 $ 875
[1] Primary program research and development expenses are comprised primarily of costs paid to third parties for clinical trials and product development manufacturing, nonclinical, regulatory, and quality assurance activities, and the portion of related research and development expenses incurred by our collaborators and third-party service providers, including contract research and manufacturing organizations that we are obligated to reimburse.
[2] Other segment income (expense), net includes interest income, interest expense, foreign currency exchange gain or loss, depreciation and amortization, non-cash stock-based compensation, loss on extinguishment of debt and tax credit income.